Fox Run Management L.L.C. Sells 12,570 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)

Fox Run Management L.L.C. cut its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) by 55.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 10,108 shares of the technology company’s stock after selling 12,570 shares during the period. Fox Run Management L.L.C.’s holdings in Cogent Biosciences were worth $79,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of COGT. Victory Capital Management Inc. bought a new position in shares of Cogent Biosciences in the third quarter worth $113,000. Intech Investment Management LLC purchased a new stake in Cogent Biosciences during the 3rd quarter worth about $307,000. Charles Schwab Investment Management Inc. boosted its stake in Cogent Biosciences by 20.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 825,793 shares of the technology company’s stock worth $8,919,000 after purchasing an additional 139,096 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Cogent Biosciences during the 3rd quarter valued at about $134,000. Finally, Bank of Montreal Can bought a new stake in shares of Cogent Biosciences during the third quarter valued at about $3,135,000.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Scotiabank began coverage on shares of Cogent Biosciences in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $17.00 price objective for the company. HC Wainwright decreased their price target on shares of Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Robert W. Baird decreased their price objective on Cogent Biosciences from $10.00 to $8.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. Wedbush reiterated a “neutral” rating and issued a $11.00 target price on shares of Cogent Biosciences in a research report on Tuesday, February 25th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Cogent Biosciences in a research report on Wednesday, February 26th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Cogent Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $14.43.

Cogent Biosciences Price Performance

Shares of NASDAQ:COGT opened at $6.48 on Friday. The business has a fifty day moving average price of $7.87 and a 200-day moving average price of $9.12. The company has a market capitalization of $737.75 million, a PE ratio of -2.61 and a beta of 1.80. Cogent Biosciences, Inc. has a 1-year low of $5.88 and a 1-year high of $12.61.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.